

RESEARCH LETTER

Open Access



Inhaled nitric oxide in patients admitted to intensive care unit with COVID-19 pneumonia

Guido Tavazzi^{1,2*}, Marco Pozzi², Silvia Mongodi², Valentino Dammassa¹, Giovanni Romito¹ and Francesco Mojoli^{1,2}

Dear Editor,

Patients with ARDS due to COVID-19 are characterised by poor oxygenation with a various extent of pulmonary alterations [1]. Ventilation strategies for COVID-19 patients have been suggested basing on the pathophysiological evidence to date [1]; however, there are no data regarding the use of inhaled nitric oxide (iNO). We report herein our experience of iNO administration in COVID-19 mechanically ventilated patients with refractory hypoxaemia and/or right ventricular (RV) dysfunction. Refractory hypoxaemia was defined as $\text{PaO}_2/\text{FiO}_2 < 100$ despite high PEEP (≥ 10 cmH₂O) and prone position. RV dysfunction was defined as acute *cor pulmonale* at echocardiography with hemodynamic impairment requiring infusion of inotropic drugs [2].

The NO/nitrogen mixture was introduced into the inspiratory limb of the ventilator tubing. Respiratory and haemodynamic parameters were collected immediately before iNO administration (t_0) and after 15–30 min (t_1). Responders were defined by an increase of $\text{PaO}_2/\text{FiO}_2 > 20\%$ compared to t_0 [3].

Results in the text are shown as median [IQR] or number (%). Wilcoxon test for paired samples and Mann-Whitney test, as appropriate (MedCalc version 19.2 MedCalc Software), were performed considering $p < 0.05$ as significant.

iNO was used in sixteen out of 72 (22.2%) consecutive mechanically ventilated patients (66.0 [59.6–69.7] years

old; 93% male). All patients required iNO for refractory hypoxaemia of whom 4 (25%) had also superimposed RV dysfunction, in 1 case associated with pulmonary embolism. The iNO dosage was 25 [20–30] parts per million (ppm).

Respiratory parameters at t_0 and t_1 are shown in Table 1. Overall, iNO did not improve oxygenation in our population. Only 4 (25%) patients were responders, of whom 3 have superimposed RV dysfunction, showing a median increase of $\text{PaO}_2/\text{FiO}_2$ of 26.9% [24.1–45.5]. A trend towards a larger improvement of oxygenation was observed in patients with RV dysfunction as compared with those without ($\text{PaO}_2/\text{FiO}_2$ increase 24.1% [9.2–43.5] vs. 3.3% [–10.8–11.5], $p = 0.069$). Additionally, in responders, $\text{PaO}_2/\text{FiO}_2$ was 125.9 [82.2–259.2] at t_1 and did not change ($p = 0.875$) 24 h later (146.4 [102.2–225.1]).

iNO is a free radical gas that diffuses across the alveolar-capillary membrane into the subjacent smooth muscle of pulmonary vessels enhancing endothelium-dependent vasorelaxation and improving oxygenation by increasing blood flow to ventilated lung units [3]. In previous studies, iNO was effective in improving $\text{PaO}_2/\text{FiO}_2$ and oxygenation index, although it failed in reversing acute lung injury, reducing mechanical ventilation days and mortality [4].

In our population, the improvement of oxygenation in responders was probably magnified by an iNO-induced decrease of RV afterload, enhancing cardiac output and finally leading to an increase of mixed venous oxygen saturation.

Although the reason why patients with refractory hypoxaemia without RV dysfunction were not responder is yet to be determined, some speculation can be done. Severe endothelial injury with cytoplasmic vacuolization

* Correspondence: guido.tavazzi@unipv.it

¹Department of Clinical-Surgical, Diagnostic and Paediatric Sciences, Unit of Anaesthesia and Intensive Care, University of Pavia, Pavia, Italy

²Anesthesia and Intensive Care, Fondazione Policlinico San Matteo Hospital IRCCS, Anestesia e Rianimazione I, DEA Piano -1, Fondazione IRCCS Policlinico S. Matteo, Viale Golgi 19, 27100 Pavia, Italy



© The Author(s). 2020, corrected publication 2020. **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>. The Creative Commons Public Domain Dedication waiver (<http://creativecommons.org/publicdomain/zero/1.0/>) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Table 1 Patients respiratory and hemodynamic parameters at the two time points

Parameter	Pre iNO (t_0)	Post iNO (t_1)	<i>p</i> value
SBP, mmHg	127.0 [114.0–137.5]	119.0 [110.0–138.0]	0.454
MAP, mmHg	83.5 [80.5–93.5]	78.0 [74.5–85.5]	0.144
HR, bpm	89.5 [80.5–99.7]	88.0 [75.0–100.0]	0.159
pH	7.27 [7.22–7.35]	7.31 [7.24–7.36]	0.049
PaCO ₂ , mmHg	59.8 [52.5–76.5]	60.9 [50.8–65.7]	0.002
PaO ₂ , mmHg	79.7 [58.9–87.2]	77.1 [63.5–88.6]	0.252
PaO ₂ /FiO ₂	91.7 [62.1–109.2]	91.5 [67.1–106.7]	0.274
MetHb, %	1.18 [1–1.3]	1.3 [1.1–1.4]	0.16
FiO ₂	87.5 [80–95]	87.5 [80–95]	1
PEEP, cmH ₂ O	13.0 [10.0–15.0]	13.0 [10.0–15.0]	1
MV, L/min	9.7 [8.1–11.3]	10.3 [8.7–11.4]	0.204
Peak pressure, cmH ₂ O	30.5 [27.5–33.5]	30.5 [26.0–33.0]	0.641

Results in the table are shown as mean [CI 95%]

SBP systolic blood pressure, MAP mean arterial pressure, HR heart rate, bpm beats per minutes, MetHb methemoglobin, PEEP positive end-expiratory pressure, MV minute volume

and cell detachment in pulmonary middle-small arteries can make the pulmonary vessels less reactive to iNO stimulation [1, 5, 6]. This could also explain the loss of hypoxic vasoconstriction and lung perfusion regulation. However, whether vascular derangements in COVID-19 are due to endothelial cell involvement by the virus, part of the ARDS pathophysiology or the intertwine of both is still undetermined. Moreover, prone position and iNO were used in refractory hypoxaemia as an escalating treatment strategy. Therefore, a positive response to the prone position may have precluded the enrolment in our study of patients that could positively respond to iNO.

Conclusion

Overall, iNO did not improve oxygenation in COVID-19 patients with refractory hypoxaemia, when administered as a rescue treatment after prone position. A subgroup of patients with RV dysfunction was better iNO responders probably due to the haemodynamic improvement associated with RV unloading.

Acknowledgements

We thank all the nurses and physicians involved in the management of such epidemics (Dr. Camporotondo Rita, Prof. Iotti Giorgio, Dr. Sciutti Fabio, Dr. Rodi Giuseppe, Dr. Orlando Anita, Dr. Maggio Giuseppe, Dr. Belliati Mirko, Dr. Radolovich Danila, Dr. Sala Gallini Giuseppe, Dr. Caneva Luca, Dr. Pagani Michele, Dr. Ferrari Fiorenza, Dr. Aliberti Anna, Dr. Visconti Federico, Dr. Repossi Filippo, Dr. Civardi Luca, Dr. Puce Roberta, Dr. Aliberti Anna, Dr. Bottazzi, Andrea, Dr. Amatu Alessandro, Dr. Lococo Claudia, Dr. Arisi Eric) and the Pavia COVID-19 Task Force (Dr. Marena Carlo, Dr. Calvi Monica, Dr. Grugnetti Giuseppina, Dr. Maurelli Marco, Dr. Muzzi Alba, Prof. Raffaele Bruno, Dr. Lago Paolo, Prof. Marseglia Gianluigi, Prof. Perlini Stefano, Dr. Palo Alessandra, Prof. Baldanti Fausto, Prof. Corsico Angelo Guido, Prof. Di Sabatino Antonio, Prof. Iotti Giorgio, Prof. Benazzo Marco, Prof. Carlo Nicora, Prof. Antonio Triarico and Dr. Vincenzo Petronella).

Authors' contributions

All authors contributed equally to the data collection and redaction, writing and final revision before submission of the paper. The author(s) read and approved the final manuscript.

Funding

No funding were received for the submitted work.

Availability of data and materials

The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.

Ethics approval and consent to participate

Informed consent was collected following the ad hoc procedures defined by the local Ethics Committee of Fondazione Policlinico San Matteo IRCCS for the COVID-19 pandemic.

Competing interests

FM received fees for lectures from GE Healthcare, Hamilton Medical, SEDA SpA, outside the present work. SM received fees for lectures from GE Healthcare, outside the present work. GT received fees for lectures by GE Healthcare, outside the present work. MP, VD and GR have nothing to disclose.

Received: 22 July 2020 Accepted: 3 August 2020

Published online: 17 August 2020

References

- Marini JJ, Gattinoni L. Management of COVID-19 respiratory distress. *JAMA*. 2020. Online ahead of print.
- Narendra DK, Hess DR, Sessler CN, Belete HM, Guntupalli KK, Khusid F, Carpati CM, Astiz ME, Raoof S. Update in management of severe hypoxemic respiratory failure. *Chest*. 2017;152:867–79.
- Ichinose F, Roberts JD Jr, Zapol WM. Inhaled nitric oxide: a selective pulmonary vasodilator: current uses and therapeutic potential. *Circulation*. 2004;109:3106–11.
- Gebistorf F, Karam O, Wetterslev J, Afshari A. Inhaled nitric oxide for acute respiratory distress syndrome (ARDS) in children and adults. *Cochrane Database Syst Rev*. 2016;2016(6):CD002787.
- Copin MC, Parmentier E, Duburcq T, Poissy J, Mathieu D, Lille C-I, Anatomopathology G. Time to consider histologic pattern of lung injury to treat critically ill patients with COVID-19 infection. *Intensive Care Med*. 2020; 46(6):1124–6.
- Varga Z, Flammer AJ, Steiger P, Haberecker M, Andermatt R, Zinkernagel AS, Mehra MR, Schuepbach RA, Ruschitzka F, Moch H. Endothelial cell infection and endotheliitis in COVID-19. *Lancet*. 2020;395(10234):1417–8.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Ready to submit your research? Choose BMC and benefit from:

- fast, convenient online submission
- thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.

Learn more biomedcentral.com/submissions

